Dehydration

scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection

Retrieved on: 
星期三, 四月 24, 2024
Urine, Kidney, FDA, Shanda, Embolism, Huber loss, Hepatic encephalopathy, Uric acid, Oliguria, Congestion, Blood volume, Furosemide, Organic acid, Deafness, Erythema, Cerebral edema, Ascites, Tinnitus, History, Thrombosis, Creatinine, NYHA, Dehydration, BUN, Patient, Hypersensitivity, Ototoxicity, Anuria, Glucose, Azotemia, Hypoproteinemia, CO2, Diuresis, Cirrhosis, Chronic kidney disease, Edema, Urinary retention, Bruise, Growth, Benign prostatic hyperplasia, Coma, Heart failure, Pharmaceutical industry

BURLINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that it has enrolled the first participant in the pivotal pharmacokinetic (PK) study of SCP-111 (furosemide 80 mg/mL), an investigational, low volume, pH neutral formulation of furosemide administered via an auto-injector.

Key Points: 
  • The auto-injector is being developed as a complement to the FDA approved On-body Infusor in an effort to provide patients with a subcutaneous injection and prescribers with treatment flexibility.
  • If approved, the Company believes the auto-injector also has the potential to meaningfully reduce manufacturing costs.
  • FUROSCIX is not indicated for use in emergency situations or in patients with acute pulmonary edema.
  • The most common adverse reactions with FUROSCIX administration in clinical trials were site and skin reactions including erythema, bruising, edema, and injection site pain.

FSIS ISSUES PUBLIC HEALTH ALERT FOR GROUND BEEF PRODUCTS DUE TO POSSIBLE E. COLI O157:H7 CONTAMINATION

Retrieved on: 
星期六, 四月 20, 2024
Food safety, Syndrome, Person, Poultry, Dysentery, Independence Avenue, Commerce, Kidney failure, USDA, Human, H7, Dehydration, HUS, TDD, Pallor, Meat, Temperature, Chronic pain, FSIS, Bruise, Office for Civil Rights, Civil and political rights, Poultry farming

WASHINGTON, April 20, 2024 – The U.S. Department of Agriculture’s Food Safety and Inspection Service (FSIS) is issuing a public health alert for ground beef products that may be contaminated with E. coli O157:H7.

Key Points: 
  • WASHINGTON, April 20, 2024 – The U.S. Department of Agriculture’s Food Safety and Inspection Service (FSIS) is issuing a public health alert for ground beef products that may be contaminated with E. coli O157:H7.
  • FSIS is issuing this public health alert to ensure that consumers are aware that these products should not be consumed.
  • The products have a “Use/Freeze by” date of April 22, 2024, and packaging date of “032824.” The list of products that are subject to the public health alert can be found here .
  • The company notified FSIS that they inadvertently used a portion of the contaminated beef to produce ground beef products that they subsequently shipped into commerce.

BranchOut Food Strengthens Financial Position with Successful Sale of Senior Secured Promissory Notes and Warrants

Retrieved on: 
星期三, 四月 17, 2024
Sale, Warrant, Food technology, Public expenditure, Senior, Dehydration, Subscription business model, Fruit, Security, Control, Security (finance)

BEND, Ore., April 17, 2024 (GLOBE NEWSWIRE) -- BranchOut Food Inc. (NASDAQ: BOF), a food technology company and maker of dehydrated fruit and vegetable-based products, today announced that it has completed the sale of $225,000 of Senior Secured Promissory Notes ("Notes") and Warrants to purchase an aggregate of 56,250 shares of the Company’s common stock.

Key Points: 
  • BEND, Ore., April 17, 2024 (GLOBE NEWSWIRE) -- BranchOut Food Inc. (NASDAQ: BOF), a food technology company and maker of dehydrated fruit and vegetable-based products, today announced that it has completed the sale of $225,000 of Senior Secured Promissory Notes ("Notes") and Warrants to purchase an aggregate of 56,250 shares of the Company’s common stock.
  • Each Warrant is exercisable for a ten-year period at an exercise price of $2.00 per share.
  • The Company has board approval to borrow up to $2,000,000 of Notes.
  • The sale was made to a group of seven investors pursuant to a First Amendment to Subscription Agreement dated April 15-16, 2024.

Global Dermocosmetic (Skin, Hair) Market Analysis Report 2024: Innovations in Bioengineering Transforming the Industry - Forecasts to 2030 - ResearchAndMarkets.com

Retrieved on: 
星期三, 四月 17, 2024
Cosmetics, Retail, General Health, Health, Online, USD, Market, Supermarket, Sale, Dermatitis, Porter's five forces analysis, Epidemiology, Acne, SWOT, Particulates, Skin, AI, Genetic engineering, John Foster Dulles, Pharmacy, Life, Dermatology, Algorithm, Dehydration, Incidence, Patient, Hyperpigmentation, Psoriasis, Dermatologic Clinics, Rosacea, Child, Beauty, Biological engineering, Urbanization, Ageing, Fermentation, UV, Prevalence, Air pollution, Beauty salon

The market was valued at USD 67.42 Billion in 2023 which is expected to reach USD 108.94 Billion in 2030.

Key Points: 
  • The market was valued at USD 67.42 Billion in 2023 which is expected to reach USD 108.94 Billion in 2030.
  • This report provides a complete analysis for the historical period of 2020-2023, estimates of 2024 and the forecast period of 2025-2030.
  • The report presents the analysis of Dermocosmetic Market for the historical period of 2020-2023, the estimated year 2024 and the forecast period of 2025-2030.
  • Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report.

Global Urine Output Monitoring Systems Market is Projected to Grow at a CAGR of ~5% by 2030 | DelveInsight

Retrieved on: 
星期四, 四月 25, 2024
Sentinel, Conditional sentence, FDA, Kidney, Nursing care plan, Urinary tract infection, Risk, Prevalence, CDC, 3i, Diabetes, Machine learning, Artificial intelligence, Intensive care unit, Urine, Patient safety, CKD, Dehydration, Patient, Operating, LAS, Data collection, Data management, Health, System, Chronic kidney disease, Intensive care medicine, Algorithm, Overalls, CE marking, Medical device

LAS VEGAS, April 25, 2024 /PRNewswire/ -- DelveInsight's Urine Output Monitoring Systems Market Insights report provides the current and forecast market analysis, individual leading urine output monitoring systems companies' market shares, challenges, urine output monitoring systems market drivers, barriers, trends, and key market urine output monitoring systems companies in the market.

Key Points: 
  • LAS VEGAS, April 25, 2024 /PRNewswire/ -- DelveInsight's Urine Output Monitoring Systems Market Insights report provides the current and forecast market analysis, individual leading urine output monitoring systems companies' market shares, challenges, urine output monitoring systems market drivers, barriers, trends, and key market urine output monitoring systems companies in the market.
  • Notable urine output monitoring systems companies such as BD, Potrero Medical Inc., 3i Group plc, Serenno Medical, RenalSense Ltd., FIZE Medical, and several others, are currently operating in the urine output monitoring systems market.
  • To read more about the latest highlights related to the urine output monitoring systems market, get a snapshot of the key highlights entailed in the Global Urine Output Monitoring Systems Market Report
    Urine output monitoring systems play a crucial role in healthcare settings, offering real-time insights into a patient's renal function and overall health status.
  • To know more about why North America is leading the market growth in the urine output monitoring systems market, get a snapshot of the Urine Output Monitoring Systems Market Outlook
    The urine output monitoring systems market dynamics are witnessing significant evolution driven by several factors.

Global Urine Output Monitoring Systems Market is Projected to Grow at a CAGR of ~5% by 2030 | DelveInsight

Retrieved on: 
星期四, 四月 25, 2024
Sentinel, Conditional sentence, FDA, Kidney, Nursing care plan, Urinary tract infection, Risk, Prevalence, CDC, 3i, Diabetes, Machine learning, Artificial intelligence, Intensive care unit, Urine, Patient safety, CKD, Dehydration, Patient, Operating, LAS, Data collection, Data management, Health, System, Chronic kidney disease, Intensive care medicine, Algorithm, Overalls, CE marking, Medical device

LAS VEGAS, April 25, 2024 /PRNewswire/ -- DelveInsight's Urine Output Monitoring Systems Market Insights report provides the current and forecast market analysis, individual leading urine output monitoring systems companies' market shares, challenges, urine output monitoring systems market drivers, barriers, trends, and key market urine output monitoring systems companies in the market.

Key Points: 
  • LAS VEGAS, April 25, 2024 /PRNewswire/ -- DelveInsight's Urine Output Monitoring Systems Market Insights report provides the current and forecast market analysis, individual leading urine output monitoring systems companies' market shares, challenges, urine output monitoring systems market drivers, barriers, trends, and key market urine output monitoring systems companies in the market.
  • Notable urine output monitoring systems companies such as BD, Potrero Medical Inc., 3i Group plc, Serenno Medical, RenalSense Ltd., FIZE Medical, and several others, are currently operating in the urine output monitoring systems market.
  • To read more about the latest highlights related to the urine output monitoring systems market, get a snapshot of the key highlights entailed in the Global Urine Output Monitoring Systems Market Report
    Urine output monitoring systems play a crucial role in healthcare settings, offering real-time insights into a patient's renal function and overall health status.
  • To know more about why North America is leading the market growth in the urine output monitoring systems market, get a snapshot of the Urine Output Monitoring Systems Market Outlook
    The urine output monitoring systems market dynamics are witnessing significant evolution driven by several factors.

Epicore Biosystems Launches Connected Hydration to Protect Industrial Athletes from Extreme Heat

Retrieved on: 
星期四, 四月 18, 2024
Climate change, University, Agriculture, Dementia, Safety, Risk, CLASS, Thermoregulation, Artificial intelligence, Skin temperature, Military personnel, American Institute, Dehydration, Privacy, SOC, App Store (iOS/iPadOS), Athlete, Chevron Corporation, Hydration, DIV, Mining, Social computing, AICPA, System and Organization Controls, Occupation, Heat, Mobile phone

CAMBRIDGE, Mass., April 18, 2024 /PRNewswire/ -- Epicore Biosystems ('Epicore'), a digital health company developing advanced sweat-sensing wearables to provide real-time personalized hydration insights for performance and safety, today announced the commercial launch of Connected Hydration. Connected Hydration is the first sweat-sensing wearable patch and mobile app that equips workers with customized, real-time insights about sweat volume loss, electrolyte loss, body temperature and body movement to inform their hydration needs ahead of adverse dehydration events. The advanced biowearable is designed to protect industrial athletes working on the frontlines of physically intensive industries including energy, construction, mining, utilities, agriculture, trucking and warehouse packaging, as well as military personnel, from dehydration, heat stress and heat-related injuries.

Key Points: 
  • CAMBRIDGE, Mass., April 18, 2024 /PRNewswire/ -- Epicore Biosystems ('Epicore') , a digital health company developing advanced sweat-sensing wearables to provide real-time personalized hydration insights for performance and safety, today announced the commercial launch of Connected Hydration .
  • Cumulative exposure to extreme heat is proven to cause cognitive decline and physiological dysfunction and impede physical performance required for industrial occupations.
  • "The trajectory of extreme heat requires connected worker solutions that go far beyond a one-size-fits-all approach.
  • To learn more about Epicore Biosystems and Connected Hydration, visit https://www.epicorebiosystems.com/ .

MigraKet® Brings the World's First Medical Food For Migraine to the U.S

Retrieved on: 
星期五, 四月 12, 2024
Migraine, Pain, Woman, Doctor of Philosophy, Vitamin, Dehydration, Oxygen, Food, Headache, Metabolism, Antioxidant, Sleep, Injection

BASEL, Switzerland, April 12, 2024 /PRNewswire/ -- International wellness brand Brain Ritual is launching MigraKet®, a revolutionary approach to migraine management developed by renowned neuroscientist and former chronic migraineur, Elena Gross, PhD. With the U.S. release of MigraKet®, sufferers of migraine can anticipate a newfound hope in managing their condition effectively.

Key Points: 
  • With the U.S. release of MigraKet®, sufferers of migraine can anticipate a newfound hope in managing their condition effectively.
  • Different from drugs, painkillers and injections that address migraine symptoms, MigraKet® is the first holistic medical food formulation for the management of a potential root cause of migraine.
  • "We want migraine sufferers to regard their pain as a helpful alarm - alerting them of a critical system breakdown.
  • Chronic migraine is defined as having headache on at least 15 days per month, with eight of these having migraine symptoms, for at least three months.

Orphan designation: Alisitol, retinol palmitate, zinc gluconate Treatment of microvillus inclusion disease, 13/11/2020 Positive

Retrieved on: 
星期二, 四月 9, 2024
Eurostat, Civil service commission, Salt, Diagnosis, Absorption, Microvillous inclusion disease, DSM-IV codes, Nutrient, Cell, Patient, Committee, Weight loss, Knowledge, Regulation, Food, EMA, IRIS, Noetics, Parenteral nutrition, Diarrhea, European, Malnutrition, COMP, Dehydration, Water, Safety, European Commission, Liver, Medicine, Pharmaceutical industry

Orphan designation: Alisitol, retinol palmitate, zinc gluconate Treatment of microvillus inclusion disease, 13/11/2020 Positive

Key Points: 


Orphan designation: Alisitol, retinol palmitate, zinc gluconate Treatment of microvillus inclusion disease, 13/11/2020 Positive

Revive Drip’s Expert IV Nurses Bring Alternative Wellness Solutions to the Greater Puget Sound Area

Retrieved on: 
星期一, 三月 25, 2024
RN, Headache, Puget Sound, Nutrient, Pound, GIG, COVID-19, Patient, Trauma, Migraine, Suite, Dehydration, Nurse practitioner, Injection, Safety, Intravenous therapy, Collection, ARNP, Nursing

GIG HARBOR, WA, March 25, 2024 (GLOBE NEWSWIRE) -- Revive Drip, a leading mobile intravenous therapy (IV) company providing customized hydration and immune-boosting therapy throughout the Puget Sound, announced today the opening of the company’s brick-and-mortar clinic in Gig Harbor, Washington. The company’s expansion marks an exciting milestone for Revive Drip, delivering expert relief through progressive IV hydration for customers seeking alternative medical solutions.

Key Points: 
  • The company’s expansion marks an exciting milestone for Revive Drip, delivering expert relief through progressive IV hydration for customers seeking alternative medical solutions.
  • Since 2021, Revive Drip has been providing convenient and effective solutions tailored to their client’s specific wellness needs within the comfort of their client’s homes.
  • We provide expert nursing assessment skills combined with hydration and immune support for temporary relief,” explained Laura Ude, RN and Chief Operating Officer of Revive Drip.
  • Our services particularly benefit clients with autoimmune diseases, chronic headaches, and those seeking alternative solutions to the traditional medical system.